BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

DiaGenic ASA Provides Study Results and Update on Key Clinical Programs


10/10/2013 11:26:15 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

OSLO, Norway--(BUSINESS WIRE)--Regulatory News: DiaGenic (OSE:DIAG) announces results from the calibration study for MCItect®, a blood based diagnostic test for Alzheimer’s disease in the pre-dementia stage. In a patient population of 157 patients diagnosed with amnestic mild cognitive impairment, MCItect® demonstrated a total prediction accuracy of 75% in detecting patients converting to Alzheimer’s disease dementia within two years. The study included 157 patients from 19 centers in Europe and the U.S. diagnosed with amnestic mild cognitive impairment, MCI, that either remained stable or progressed to Alzheimer’s disease dementia during a two-year period. The primary goal of the study was to verify a gene expression test that predicts which patients remain stable and which progress to Alzheimer’s disease dementia within two years, based on a larger and more ethnically diverse patient population. The total prediction accuracy of this enhanced version of MCItect® was 75%, with 75% sensitivity and 73% specificity. This result is based on the total study population, including sixteen statistical outliers of which at least six were considered potentially misdiagnosed.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES